ANANDA Scientific Announces a Clinical Trial Evaluating Nantheia™ ATL5, in the treatment of Co-Occurring Opioid Use Disorder and Chronic Pain
ANANDA Scientific Inc., a research-focused biopharmaceutical company, today announced the commencement of a clinical trial evaluating Nantheia™ ATL5, an investigational drug using cannabidiol (CBD), leveraging ANANDA’s proprietary delivery technology, co-administered with delta-9-tetrahydrocannabinol (THC), for its potential efficacy in treating co-occurring opioid use disorder (OUD) and chronic pain. (Clinical Trials.gov Identifier: NCT06544291)
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241015941899/en/
(Photo: Business Wire)
The trial will be conducted at the Yale School of Medicine. The study will be led by Principal Investigator Joao P. De Aquino, M.D., Director of the Pain and Addiction Interaction Neurosciences (PAIN) Laboratory, and Assistant Chief of Inpatient Psychiatry at Yale School of Medicine. Funding for this trial is through a grant from the National Institute on Drug Abuse (NIDA).
The primary objective of this trial is to investigate the therapeutic potential of Nantheia™ ATL5, co-administered with THC, in relieving both pain and cue-induced craving in people with OUD and chronic pain. The secondary objective is to determine if adding a THC dose independently alters the effect of Nantheia™ ATL5 (CBD) alone.
This will be a randomized, double blind, placebo controlled, cross over study with participants who are maintained on stable doses of methadone randomly assigned to receive single doses of Nantheia™ ATL5 (CBD 200mg, 400mg or placebo), with THC (5mg, 10mg or placebo).
“We are excited to collaborate with ANANDA to get this trial underway,” said Dr. De Aquino. “Understanding how CBD, co-administered with low doses of THC, may work together to benefit patients with OUD and chronic pain could lead to significant advancements in treating these debilitating conditions.”
“We are delighted to be working with Dr. De Aquino and Yale School of Medicine on this important trial for our investigational drug Nantheia™ ATL5,” said Sohail R. Zaidi, ANANDA’s Chief Executive Officer. “This clinical trial is a further important step in our clinical development efforts focused on opioid addiction, where a non-addictive therapy is a significant unmet medical need.”
ABOUT NANTHEIA™ ATL5
Nantheia™ ATL5 is an investigational drug that combines cannabidiol with ANANDA’s proprietary Liquid Structure™ delivery technology. Pre-clinical and initial clinical studies show that ANANDA’s Liquid Structure™ delivery technology (licensed from Lyotropic Delivery Systems (LDS) Ltd in Jerusalem, Israel) enhances the effectiveness, consistent absorption and stability of cannabidiol. Nantheia™ ATL5 is an oral product with 100 mg of cannabidiol per softgel capsule.
About ANANDA Scientific
ANANDA Scientific is a leading research-focused biopharmaceutical company focused on developing life changing medicines to transform neuropsychiatric health. The company is currently conducting high-caliber clinical studies evaluating therapeutic indications such as PTSD, Pain, Anxiety, Opioid Use Disorder and Smoking Cessation. The company’s patented delivery technology makes cannabinoids and plant-derived compounds highly bioavailable, water-soluble, and shelf-life stable. ANANDA Scientific is dedicated to producing effective, premium pharmaceutical products that enhance patients’ lives.
This press release includes forward-looking statements that involve risks and uncertainties. Such statements are based on current assumptions and expectations, which may change over time.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241015941899/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Viromed Medical AG reaches milestone for cooperation with multinational corporation28.2.2025 20:02:00 CET | Press release
Viromed Medical AG (Ticker: VMED; ISIN: DE000A3MQR65) has reached a milestone in the extensive cooperation with a multinational corporation announced via ad hoc notification on 11 December 2024. The subject of the agreement now concluded is, in particular, the granting of a European license right in favour of Viromed Medical AG for the use of cold atmospheric pressure plasma in medicine. By granting the license rights, Viromed Medical AG is considered a manufacturer of ViroCAP® systems for use in dermatology within the meaning of the Medical Device Regulation (MDR). All intellectual property (IP) rights and the resulting patents and exploitation rights from the two companies' studies on the use of the PulmoPlas® system in pulmonary medicine are held solely by Viromed Medical AG. relyon plasma GmbH, a subsidiary of TDK Electronics AG, will produce both the ViroCAP® systems and the PulmoPlas® systems on behalf of Viromed Medical. The special approval by the Federal Institute for Drugs an
Canoga Perkins Launches Private 5G with TSN Demo, Showcasing a Streamlined way to Deploy Private 5G for Industrial and Enterprise Use Cases28.2.2025 19:21:00 CET | Press release
A simple, secure, and high-performance Private 5G deployment is demonstrated, leveraging Moso® Networks’ radios and Canoga Perkins’ SyncMetra™ transport solution Network connectivity solutions provider, Canoga Perkins today announces the launch of its Private 5G with Time-Sensitive Networking (TSN) demonstration in its Customer Experience Center (CEC). This demo serves as a model for how Private 5G should be deployed, offering a streamlined, reliable, and secure approach for industrial and enterprise applications. The setup integrates the Moso Canopy 5GID2 radio and Canoga Perkins’ switch and transport solution, SyncMetra, creating a comprehensive, best-in-class Private 5G solution. The combination of these technologies simplifies the deployment process, reduces complexity, and ensures high performance for mission-critical applications. “Private 5G has the potential to revolutionize industrial and enterprise connectivity, but only if deployed correctly,” said Malik Arshad, CEO of Canog
Venture Global, Inc. Announces Record Date for Cash Dividend28.2.2025 18:56:00 CET | Press release
The Venture Global, Inc. (“Venture Global”) (NYSE: VG) board of directors determined today that the per share amount of its previously declared cash dividend shall be $0.0165 per share, or approximately $40 million in the aggregate, payable on March 31, 2025 to holders of its outstanding Class A common stock and outstanding Class B common stock, and that the record date shall be the close of business on March 10, 2025. About Venture Global Venture Global is a long-term, low-cost provider of U.S. LNG sourced from resource rich North American natural gas basins. Venture Global’s business includes assets across the LNG supply chain including LNG production, natural gas transport, shipping and regasification. Venture Global’s first facility, Calcasieu Pass, commenced producing LNG in January 2022. The company’s second facility, Plaquemines LNG, achieved first production of LNG in December 2024. The company is currently constructing and developing over 100 MTPA of nameplate production capac
Andersen Global styrker værdiansættelseskapaciteten i Etiopien med ny samarbejdsvirksomhed28.2.2025 16:00:00 CET | Pressemeddelelse
Andersen Global udvider sin tilstedeværelse i Afrika med samarbejdsvirksomheden ADS Valuation Services PLC. Dette forbedrer værdiansættelseskapaciteten og konsoliderer platformen i Etiopien. ADS Valuation Services PLC, der har sit hovedkontor i Addis Abeba, udfører værdiansættelse for virksomheder og investorer og rådgiver disse om blandt andet anlægsaktiver og løsøregenstande, immaterielle aktiver og ansættelser af virksomheder ved hjælp af et omfattende udvalg af værdiansættelsestjenester. "Engagementet i vores team ligger i servicering af virksomheder og investorer gennem skræddersyede løsninger og ved udnyttelse af vores brancheekspertise," siger General Manager Adnan Esmael. "Med et etiopisk forretningslandskab i så hastig udvikling, understreget af den nylige lancering af landets første værdipapirbørs og forskellige politiske ændringer, der tiltrækker udenlandske investeringer, er der unikke muligheder for vækst. Samarbejdet med Andersen Global forstærker vores engagement i kunde
Incyte to Unveil New Data from its Dermatology Portfolio at 2025 American Academy of Dermatology (AAD) Annual Meeting28.2.2025 15:30:00 CET | Press release
- Featured abstracts for ruxolitinib cream (Opzelura®) include multiple presentations in atopic dermatitis and late-breaking data in prurigo nodularis (PN) - Pipeline data presented includes data for axatilimab (Niktimvo™) in patients with dermatologic manifestations of chronic graft-versus-host disease (GVHD) Incyte (Nasdaq: INCY) today announced that multiple abstracts featuring new data from its dermatology portfolio will be presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting, being held March 7–11, 2025, in Orlando. "We look forward to sharing new data for ruxolitinib cream (Opzelura®) across multiple indications, including prurigo nodularis, and axatilimab (Niktimvo™) in patients with dermatologic manifestations of chronic graft-versus-host disease (GVHD) at this year's AAD Annual Meeting,” said Jim Lee, M.D., Ph.D., Group Vice President, Inflammation and Autoimmunity, Incyte. "Incyte’s active participation in this key congress reinforces our commitment to a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom